Lutris, Pharma

Lutris Pharma Presents Additional Positive Data from Its Phase 2 Trial of LUT014 Gel Demonstrating Significant Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies at the ESMO Gastrointestinal Cancers Congress 2025

Published on 08/07/2025 at 18:06 | prnewswire.co.uk

Lutris Pharma Israel New York

View original content:https://www.prnewswire.co.uk/news-releases/lutris-pharma-presents-additional-positive-data-from-its-phase-2-trial-of-lut014-gel-demonstrating-significant-efficacy-in-treating-acneiform-rash-associated-with-use-of-anti-egfr-cancer-therapies-at-the-esmo-gastrointestinal-canc-302498945.html

en | boerse | 67958808 |